Equities
Elmera Group posts 30% rise in Q2 2026 EBIT as Fortum deal review advances
Norwegian energy group Elmera Group reported a 30.1% increase in adjusted EBIT to NOK 121 million for Q2 2026, while Fortum’s NOK 47 per share cash offer remains under regulatory review.
Swiss SMI edges higher; Geberit surges 8% on strong half-year results
Swiss SMI opens 0.21% higher as Geberit leads gains with an 8% jump following better-than-expected half-year earnings. Implenia, Sensirion and Sunrise also advance, while Straumann, BKW and Emmi decline.
European stocks fall to two-week lows; bond yields climb ahead of ECB, Fed signals
Stoxx Europe 600 drops for sixth straight session as yields surge to multi-year highs; ECB chief economist flags persistent inflation risks. U.S. Treasury expands bond buybacks.
German DAX slips 0.14% as rate jitters persist, chip stocks weigh
The German benchmark index closed modestly lower as rising bond yields and Middle East tensions kept investors cautious. Chip stocks led declines, with Infineon down 4%, while SAP and Merck advanced on positive sector news.
Straumann reports 2.3% revenue growth in H1, CEO Daniellot to step down
Swiss dental implant maker posts 1.38 billion francs in first-half sales, trims full-year outlook amid leadership transition.
Workday forms AI research unit, launches PhD fellowship program
New team will focus on enterprise-grade AI systems while the fellowship provides $50,000 annually to doctoral students in partnership with universities.
Yixin Group posts 31% profit growth in H1 2026 despite share drop
China’s auto financing platform Yixin Group reported a 31% rise in adjusted net profit to RMB 850 million for the first half of 2026, driven by FinTech and SaaS revenue growth. Shares fell 3.8% on the news.
DAX edges higher as tech rebound offsets rate, geopolitical risks
German blue-chip index recovers early losses; chipmakers rebound on deal flow and buybacks. Euro Stoxx 50, MDAX also advance as U.S. futures point higher.
Revelation Biosciences picks Avance Clinical for AKI trial
Contract research organization Avance Clinical will oversee Revelation’s Phase 2/3 TITAN study of its Gemini drug for acute kidney injury, with enrollment expected to begin later in 2026.
Swiss SMI rises 0.21% as oil climbs fourth day; Geberit, Implenia surge on earnings
Geberit surged 8% after beating half-year expectations, while Implenia jumped 9% on strong growth outlook. Brent crude rose 0.7% to $91.61 as Iran conflict persists; BKW and Straumann fell 4.5%.
Elmera posts 30% profit jump as Fortum takeover review continues
Norwegian energy group Elmera reported a 30% rise in second-quarter adjusted EBIT to NOK 121 million, while its debt fell sharply to NOK 1.04 billion amid an ongoing cash tender offer by Fortum.
Dax slips on weak tech cues, global equities pressure mounts
German benchmark index faces modest losses after semiconductor shares retreat in Asia and U.S. tech weakness. Heidelberger Druckmaschinen and Redcare Pharmacy diverge on earnings updates.
Goldman Sachs upgrades Japan’s top electronic component stocks on AI demand
Analysts at Goldman Sachs raise price targets and earnings forecasts for nine Japanese electronic component makers, citing surging AI server and data center demand. Ibiden, Murata and Taiyo Yuden highlighted for strongest margin and sales revisions.
Straumann names Christopher Norbye as next CEO, effective Dec 1
Guillaume Daniellot to step down after nearly 20 years, including seven as CEO. Norbye joins from Beijer Ref, where revenue doubled and profit tripled under his leadership.
Swiss SMI slips as 19 of 20 components fall; Geberit, DocMorris advance on earnings
The Swiss blue-chip index was set to open lower, with Geberit the sole gainer after strong half-year results. DocMorris surged 8% on earnings, while BKW dropped 3%. Global yields near multi-decade highs weighed on risk assets.
Complete Genomics appoints Lauren Selig to board ahead of Swiss Rockets deal
Selig joins as Swiss Rockets AG prepares to acquire the DNA sequencing firm, pending U.S. regulatory clearance. Her appointment reflects the deal's focus on precision healthcare and biotech innovation.
InterCure sets 1-for-5 reverse stock split for Aug. 24, 2026
The move aims to lift the share price above Nasdaq’s $1 minimum bid requirement. Trading will continue under the same ticker INCR.
Zaptec posts record Q2 revenue as EV charging orders surge 94%
Norwegian EV charging firm Zaptec reported a 32% revenue increase to 506 million NOK in Q2 2026, while order intake nearly doubled to 894 million NOK. EBITDA rose 57% to 69 million NOK as margins expanded.
Zaptec posts record Q2 2026 revenue, shares rise 0.3%
Norwegian EV charging firm Zaptec reported 506 million NOK in revenue, up 32% YoY, while order intake surged 94%. Shares edged up 0.32% to $47.50 in early trading.
Burckhardt Compression plans up to 220 job cuts in restructuring drive
Swiss compressor maker to slash up to 150 roles in Winterthur and 70 internationally, targeting annual savings of 20 million francs by 2026.
Straumann posts 7.8% organic revenue growth in H1, confirms 2026 outlook
Zahnimplantatehersteller Straumann reports 2.3% total revenue growth to CHF 1.38 billion in H1, with organic sales up 7.8%. CEO transition announced as Daniellot steps down after seven years.
Emmi posts 2.2% revenue rise in H1 2026, lifts annual outlook
Swiss dairy group Emmi reports stronger-than-expected first-half growth, with revenue up 2.2% to CHF 2.32bn, while maintaining full-year EBIT and net margin guidance.
KME plans Frankfurt IPO for copper-nickel unit Cunova worth up to $1.2 bln
Italian metals group KME has selected Berenberg and UniCredit to lead an IPO for its copper-nickel unit Cunova in Frankfurt, with a potential valuation of €1 billion. Listing could occur in 2026 or 2027.
Geberit lifts H1 sales on volumes, price hikes; shares surge 7%
Swiss sanitary products maker posts 2.8% reported net sales growth in first half, driven by higher volumes and pricing, while maintaining full-year guidance. Shares jump over 7% on strong Q2 beat.